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Protective Effect of Galega officinalis Extract on 
Streptozotocin-Induced Kidney Damage and Biochemical 
Factor in Diabetic Rats
Introduction
Diabetes mellitus (DM) is one of the most public 
metabolic sicknesses result from the lack of insulin or the 
presence of insulin resistance in peripheral tissues or both 
that is accompanied by high blood glucose concentration 
(1,2). The complications of diabetes are major health 
problems in developed and developing countries (2). It 
affects approximately 4% of the population worldwide and 
is estimated to increase by 5.4% in 10 years later (3). In 
diabetes, chronic hyperglycemia is associated with long-
term damages, dysfunction and eventually the failure of 
organs, especially the eyes, kidneys, cardiovascular system, 
and nerves (3). Besides hyperglycemia, other factors such 
as, dyslipidemia and hyperlipidemia are also involved in 
the development of cardiovascular complications which 
are the major cause of morbidity and mortality (4,5). 
Nowadays, the available therapies for diabetes include 
insulin and/or various oral chemical antidiabetic drugs, 
including sulfonylureas, thiazolidinediones, α-glucosidase 
inhibitors, etc. Each of the above-mentioned oral 
antidiabetic agents is associated with a number of serious 
adverse effects (6). Medicinal plants may play an important 
role in the management of blood glucose through different 
mechanisms. Some medicinal plants may contain insulin-
like substances (7), inhibit insulin’s activity or increase 
beta β-cells in the pancreas by activating the regeneration 
of this cells (8,9), or some may serve as antioxidants by 
reducing the oxidative stress due to free radicals in the 
pancreas (10,11). Galega officinalis (Papilionaceae) is a 
native plant from southeastern Europe and was used in the 
traditional medicinal system of Bulgaria, Italy, and India 
(12,13) in the treatment of DM (14). A biologically active 
alkaloid galegine, exhibiting a hypoglycemic effect in vivo 
was isolated from G. officinalis (15). The discovery of the 
plant’s active hypoglycemic factor led to the expansion of 
metformin, a biguanide which has been used to treat type 
2 DM (14,16). In fact, the only example of an approved 
antidiabetic drug that was extending from an herbal 
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source with a long history of use for diabetes is metformin 
from G. officinalis (17). According to the diabetes causes, 
damage to organs and tissues such as the kidneys, the 
purpose of this study was evaluated protective effects of G. 
officinalis on the kidney damage and biochemical factors 
associated with diabetes. 
Materials and Methods
Animals
 For this study was used 28 male Wistar rats weighing 200-
250 g. Rats were maintained for 2 weeks on the same diet. 
They had free access to the rat chow and tap water and 
were kept at 25°C with a 12 h/12 h light/dark cycle. All 
experimental methods were administered in accordance 
with Gonabad University of Medical Science guidelines 
for cares and use of laboratory animals.
Animal Preparation
The rats randomly divided into a 7-rat healthy control 
group and 21-rat experimental groups. In the experimental 
groups, diabetes was induced by intraperitoneal injection 
of a single dose of 50 mg/kg streptozotocin (STZ) (Sigma) 
dissolved in 5 mM citrate buffer (pH = 4.5). After 72 hours 
of injection, the rats with blood glucose levels more than 
250 mg/dL were confirmed to be diabetic. Diabetic rats 
were randomly grouped as follows, 7 rats each; the diabetic 
control (DC) received glycerol 20% in normal saline as 
vehicle, diabetic rats treated with 50 mg/kg hydroalcoholic 
extract of G. officinalis (DHEG), and diabetic rats treated 
with 5 mg/kg glibenclamide as standard drug (DG). All 
the groups were received the corresponding treatment 
once per day for 20 days, intraperitoneally. In the control 
group (normal), the same volume of citrate buffer was 
injected instead STZ. After the treatment period which 
lasts for 21 days, rats were anesthetized and their blood 
samples were drawn, and also their kidneys, livers, and 
pancreases were kept in -70°C. Blood samples were used 
for testing of glucose, insulin, lipid profile, some oxidative 
stress markers, and antioxidant enzymes their hearts 
serum samples were stored at -70°C.
Kidneys Weight
In order to measure the weight of kidneys, right and left 
removed kidneys of rat bodies were weighed by a digital 
scale, respectively.
Histopathological Studies
The species were fixed in 10% formalin, then dehydrated 
and embedded in paraffin to 5 µm cutting by a microtome. 
Finally, all of the species were stained by hematoxylin-
eosin (H & E) staining. For this propose, some slides 
were used to evaluate the histological changes and other 
of slides were used to evaluate the glomeruli and urinary 
space diameters.
Morphological Parameters
The stained samples by H & E in the previous stage were 
carried out to measure diameters and number changes of 
glomeruli and urinary spaces. ImageJ software was used 
to measurement.
PAS Stain to Evaluate the Basic Membrane
In order to measure the thickness of the basement 
membrane, periodic acid–Schiff (PAS) staining was used.
Serum Glucose and HDL and LDL Assays and Cholesterol 
Levels
At the beginning of the study, blood glucose levels were 
determined using a portable glucometer on samples 
collected from the tip of the tail vein. At the end of the 
study, serum glucose levels were determined using 
commercial kits (Parsazmun, Iran). The value was 
expressed in the unit of mg/dL.
Assay of Serum Insulin Level
Serum insulin levels were measured by a method based on 
enzyme-linked immunosorbent assay (ELISA) using the 
commercial kit of Rat Insulin (Mercodia).
 
Assay of Serum Glutamate-Pyruvate Transaminase Level
The serum level of glutamate-pyruvate transaminase 
(GPT) was assayed using the method of Parsazmun kit.
Statistical Analysis 
One-way analysis of variance (ANOVA) followed by a 
multiple two-tailed t test was used for the analysis of 
significant differences among the collected data. P < 0.05 
was considered as significant difference.
Results
Kidneys Weight
The kidneys weight was significantly increased in the 
DC group as compared with the normal group (P < 0.05). 
Also, in the DG and DHEG groups, the kidneys weight 
was significantly reduced as compared with the DC group 
(P < 0.05). However, kidneys weight was significantly 
reduced in the DHEG group than the normal group 
(P < 0.05) (Figure 1).
Histological Parameters of Kidneys
The glomerular diameters were significantly increased 
in the DC group as compared with the normal group 
(P < 0.05). The glomerular diameters were significantly 
reduced in the treated groups of DG and DHEG (P<0.05). 
The diameters of urinary spaces (around the glomeruli) 
were significantly decreased in the DC group as compared 
with the normal group (P < 0.05). The urinary space 
diameters were increased in the DG and DHEG groups 
as compared with the DC group (P < 0.05). The number 
of glomeruli was significantly decreased in the DC group 
as compared with the normal group (P < 0.05). Also, it was 
increased in the DG and DHEG groups as comparing with 
the DC group (P < 0.05). But, in the therapeutic groups of 
DG and DHEG, the number of glomeruli was lower than 
the normal group (P < 0.05; Table 1) (Figure 2).
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Thickness of the Basement Membrane
Evaluation of the basement membrane in different groups 
showed that the thickness of the basement membrane was 
increased in the diabetic control group than the normal 
group. Moreover, in the DG and DHEG groups, the 
Table 1. Comparison the Glomerular Diameters and Diameters of Urinary Space and Number of Glomeruli in Normal, DC, DG and DHEG 
Groups
Group Glomerular Diameters Diameters of Urinary Space Number of Glomeruli
Normal 258.94±2.085 35.5± 1.16 32137.5±331.84
DC 339.13 ±12.70 21.88± .82 21841.75±161.62
DG 239.90±  10.68* 34.70± .65* 24399.75±280.18*
DHEG 247.86±4.88* 32.08± .44* 25388.75±491.30*
Normal; The healthy control group receiving normal saline. DC; diabetic control group, receiving normal saline. DG; Treated with 5 mg/kg 
glibenclamide. DHEG; A diabetic group that receiving 50 mg/kg hydroalcoholic extracts of Galega officinalis.
The asterisk * shows significant difference with the DC group and the symbol of  means the significant difference with the Normal group 
(P ≤ 0.05).
 Fig-4: Comparison the serum level of Creatinin in Normal, DC, DG and DHEG groups. Normal; The healthy control group 
receiving normal saline. DC; diabetic control group, receiving normal saline. DG; Treated with 5 mg/kg glibenclamide. DHEG; 
A diabetic group that receiving 50 mg/kg hydroalcholic extracts of Galega officinalis. 
The asterisk * shows significant difference with the Normal group and the symbol of + means the significant difference with 
the DC group. (P≤0.05). 
 
Fig-5: omparison the serum level of urea in Normal, DC, DG and DHEG groups. Normal; The healthy control group receiving 
normal saline. DC; diabetic control group, receiving normal saline. DG; Treated with 5 mg/kg glibenclamide. DHEG; A diabetic 
group that receiving 50 mg/kg hydroalcholic extracts of Galega officinalis. 
The asterisk * shows significant difference with the Normal group and the symbol of + means the significant difference with 
the DC group. (P≤0.05). 
 
Fig-6: Comparison the serum level of GPT in Normal, DC, DG and DHEG groups. Normal; The healthy control group 
receiving normal saline. DC; diabetic control group, receiving normal saline. DG; Treated with 5 mg/kg glibenclamide. 
DHEG; A diabetic group that receiving 50 mg/kg hydroalcholic extracts of Galega officinalis. 
The asterisk * shows significant difference with the Normal  group and the symbol of + means the significant difference with 
the DC group. (P≤0.05). 
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Figure 1. Comparison the Kidney Weight in Normal, DC, DG and 
DHEG groups. Normal; The healthy control group receiving normal 
saline. DC; diabetic control group, receiving normal saline. DG; 
Treated with 5 mg/kg glibenclamide. DHEG; A diabetic group that 
receiving 50 mg/kg hydroalcoholic extracts of Galega officinalis.The 
Asterisk sign shows significant difference with the Normal group 
and the symbol of  means the significant difference with the DC 
group (P ≤ 0.05).
Figure 2. Histological parameters, H&E staining: (1) Normal; The 
healthy control group receiving normal saline. (2) DC; diabetic 
control group, receiving normal saline. (3) DG; Treated with 5 mg/
kg glibenclamide. (4) DHEG; A diabetic group that receiving 50 mg/
kg hydroalcoholic extracts of Galega officinalis.
basement membrane thickness was lower than the DC 
group (Figure 3).
Fasting Blood Level of Glucose
Fasting blood sugar (FBS) levels were significantly 
increased in the DC group as compared with the normal 
group (P < 0.05). Comparisons between the DC, DG, and 
DHEG groups were showed a significant decrease in the 
DG and DHEG groups as compared with the DC group 
(P < 0.05; Figure 4).
Serum Insulin Level
The serum insulin level was significantly decreased in 
all groups of DC, DG, and DHEG as compared with the 
normal group (P < 0.05), and also it was increased in the 
DG and DHEG groups as compared with the DC group. 
The increase in the DHEG group was significant (P < 0.05; 
Figure 5).
Serum Lipid Profile
Serum level of cholesterol: The serum level of cholesterol 
was significantly increased in the DC group as compared 
with the normal group (P < 0.05). Moreover, the cholesterol 
level was significantly decreased in all groups of the DG 
and DHEG as compared with the DC group (P < 0.05; 
Table 2).
Serum level of low-density lipoprotein (LDL): The serum 
level of LDL was showed a slight increase in the DC group 
as compared with the normal group (P > 0.05). The level 
of LDL was significantly reduced in the DG and DHEG 
groups as compared with the DC group (P < 0.05; Table 2).
Serum level of high-density lipoprotein (HDL): The serum 
level of HDL was significantly decreased in the DC group 
as compared with the Normal group (P < 0.05). Also, it 
was significantly increased in the DG and DHEG groups 
as compared with the DC group (P < 0.05). On the other 
hand, the level of HDL was showed an insignificantly 
increase in the DHEG group as compared with normal 
group (P > 0.05; Table 2)
Serum level of triglycerides (TG): The serum level of TG 
was significantly increased in the DC group as compared 
with the Normal group (P < 0.05). Moreover, the level of 
TG was significantly decreased in the DHEG group as 
compared with the DC group (P < 0.05; Table 2).
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Serum level of creatinine (Cr): The serum level of Cr was 
significantly increased in the DC group as compared with 
the Normal group (P < 0.05). Also, the level of Cr was 
significantly decreased in the DG and DHEG groups as 
compared with the DC group (P < 0.05; Figure 6).
Serum level of urea: The serum level of urea was 
significantly increased in the DC group as compared with 
the Normal group (P < 0.05). Furthermore, the level of urea 
was significantly decreased in the DG and DHEG groups 
as compared with the DC group (P < 0.05; Figure 7).
Serum level of GPT: The serum level of GPT was 
significantly increased in the DC group as compared 
with the normal group (P < 0.05). Moreover, the level of 
GPT was showed a significant difference in the DG and 
DHEG groups as compared with the DC group (P < 0.05; 
Figure 8).
Discussion
At the moment, extant drug regimens to control DM 
have some drawbacks, therefore, needs to find out safer 
and more efficient antidiabetic drugs are felt (18-20). DM 
causes a disorder in the absorbent of glucose as well as 
glucose metabolism. A single dose of STZ as low as 50 
Table 2. Comparison the Serum Level of Cholesterol, HDL, LDL and TG in Normal, DC, DG and DHEG groups
Group TG (mg/dL) LDL (mg/dL) HDL (mg/dL) Cholesterol (mg/dL)
Normal 38.5965±1.58 21.1474±1.51 43.6894±1.59 73.0150±2.32
DC 62.3747±4.58 23.2278±3.68 30.9222±0.53 79.9289±1.04
DG 48.0503±2.59* 16.0891±2.99* 39.9676±2.61* 72.9426±2.30*
DHEG 35.7895±4.13* 11.9152±2.03* 45.2413±1.15* 68.5726±3.37*
Normal; The healthy control group receiving normal saline. DC; diabetic control group, receiving normal saline. DG; Treated with 5 mg/kg 
glibenclamide. DHEG; A diabetic group that receiving 50 mg/kg hydroalcoholic extracts of Galega officinalis.
The asterisk * shows significant difference with the DC group and the symbol of  means the significant difference with the Normal group 
(P ≤ 0.05).
mg/kg produces an incomplete destruction of pancreatic 
beta cells even though the rats become permanently 
diabetic (21). The purpose of this study was to evaluate 
the potential of the effectiveness of G. officinalis on blood 
biochemical factors associated with diabetes in rats which 
Figure 3. Histological Parameters, PAS staining: (1) Normal; The healthy control group receiving normal saline. (2) DC; diabetic control group, 
receiving normal saline. (3) DG; Treated with 5 mg/kg glibenclamide. (4) DHEG; A diabetic group that receiving 50 mg/kg hydroalcoholic 
extracts of Galega officinalis.
 Fig-4: Comparison the serum level of Creatinin in Normal, DC, DG and DHEG groups. Normal; The healthy control group 
receiving normal saline. DC; diabetic control group, receiving normal saline. DG; Treated with 5 mg/kg glibenclamide. DHEG; 
A diabetic group that receiving 50 mg/kg hydroalcholic extracts of Galega officinalis. 
The asterisk * shows significant difference with the Normal group and the symbol of + means the significant difference with 
the DC group. (P≤0.05). 
 
Fig-5: Comparison the serum level of urea in Normal, DC, DG and DHEG groups. Normal; The healthy control group receiving 
normal saline. DC; diabetic control group, receiving normal saline. DG; Treated with 5 mg/kg glibenclamide. DHEG; A diabetic 
group that receiving 50 mg/kg hydroalcholic extracts of Galega officinalis. 
The asterisk * shows significant difference with the Normal group and the symbol of + means the significant difference with 
the DC group. (P≤0.05). 
 
Fig-6: Comparison the serum level of GPT in Normal, DC, DG and DHEG groups. Normal; The healthy control group 
receiving normal saline. DC; diabetic control group, receiving normal saline. DG; Treated with 5 mg/kg glibenclamide. 
DHEG; A diabetic group that receiving 50 mg/kg hydroalcholic extracts of Galega officinalis. 
The asterisk * shows significant difference with the Normal  group and the symbol of + means the significant difference with 
the DC group. (P≤0.05). 
 
 
 
 
 
Fig-1 
 
Fig-2 
*

*
.00
.50
1.00
1.50
2.00
2.50
Normal DC DG DHEG
K
id
n
ey
s 
w
ei
gh
t(
gr
)
Groups
*
+
+
.
50.
100.
150.
200.
250.
300.
350.
Normal DC DG DHEG
Fa
st
in
g 
b
lo
o
d
 le
ve
l o
f 
gl
u
co
se
 
(m
g/
d
L)
Groups
Figure 4. Comparison the Fasting Blood Level of Glucose in Normal, 
DC, DG and DHEG groups. Normal; The healthy control group 
receiving normal saline. DC; diabetic control group, receiving 
normal saline. DG; Treated with 5 mg/kg glibenclamide. DHEG; 
A diabetic group that receiving 50 mg/kg hydroalcoholic extracts 
of Galega officinalis. The asterisk sign shows significant difference 
with the Normal  group and the symbol of + means the significant 
difference with the DC group (P ≤ 0.05).
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were diabetic with the method of induced-STZ. The 
results of this study showed that intraperitoneal injections 
of 50 mg/kg of STZ Could be induced hyperglycemia and 
diabetes in rats during 72 hours. Nabi et al showed that 
50 mg/kg of STZ could be induced hyperglycemia and 
diabetes during 72 hours (22). Also, Kumar et al induced 
diabetes type 1 by intraperitoneal injection of STZ that 
was solved in the citrate buffer (pH=4.7) (23). In the 
present study, after confirming hyperglycemia in rats, to 
control blood sugar was used G. officinalis extract that the 
treatment with the extract of this plant was able to greatly 
control the blood sugar in diabetic rats. The reasons of its 
anti-hyperglycemic are the compounds such as alkaloids, 
flavonoids, glycosides, resin, steroids, tannins, and 
phenols which according to the research conducted that 
these compounds have antidiabetic trait (24). Also, Shen 
stated that Galega due to having Bygvanydyn composition 
has similar function with metformin. Therefore, it can 
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Figure 5. Comparison the Serum Level of Insulin in Normal, 
DC, DG and DHEG groups. Normal; The healthy control group 
receiving normal saline. DC; diabetic control group, receiving 
normal saline. DG; Treated with 5 mg/kg glibenclamide. DHEG; 
A diabetic group that receiving 50 mg/kg hydroalcoholic extracts 
of Galega officinalis. The asterisk sign shows significant difference 
with the Normal  group and the symbol of + means the significant 
difference with the DC group (P ≤ 0.05).
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Figure 6. Comparison the Serum Level of Creatinine in Normal, 
DC, DG and DHEG groups. Normal; The healthy control group 
receiving normal saline. DC; diabetic control group, receiving 
normal saline. DG; Treated with 5 mg/kg glibenclamide. DHEG; 
A diabetic group that receiving 50 mg/kg hydroalcoholic extracts 
of Galega officinalis. The asterisk sign shows significant difference 
with the Normal  group and the symbol of + means the significant 
difference with the DC group (P ≤ 0.05).
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Figure 7. Comparison the Serum Level of Urea in Normal, DC, DG 
and DHEG groups. Normal; The healthy control group receiving 
normal saline. DC; diabetic control group, receiving normal saline. 
DG; Treated with 5 mg/kg glibenclamide. DHEG; A diabetic 
group that receiving 50 mg/kg hydroalcoholic extracts of Galega 
officinalis. The asterisk sign shows significant difference with the 
Normal  group and the symbol of + means the significant difference 
with the DC group (P ≤ 0.05).
Figure 8. Comparison the Serum Level of GPT in Normal, DC, DG 
and DHEG groups. Normal; The healthy control group receiving 
normal saline. DC; diabetic control group, receiving normal saline. 
DG; Treated with 5 mg/kg glibenclamide. DHEG; A diabetic 
group that receiving 50 mg/kg hydroalcoholic extracts of Galega 
officinalis. The asterisk sign shows significant difference with the 
Normal  group and the symbol of + means the significant difference 
with the DC group (P ≤ 0.05).
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with 5 mg/kg glibenclamide. DHEG; A diabetic group that receiving 50 mg/kg hydroalcoholic extracts of Galega officinalis. 
The asterisk * shows significant difference with the DC group and the symbol of  means the significant difference with the 
Normal group (P≤0.05). 
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be supposed that Galega can be useful to reduce blood 
sugar (25). This reason can be assumed as the antidiabetic 
effects of Galega. Also, to compare the severity of glucose 
lowering used of glibenclamide that the severity of the 
same condition of glucose lowering in both groups was 
almost identical. As Rajasekaran et al for comparison the 
power of glucose lowering used of groups were treated 
with glibenclamide (26). The comparison of serum insulin 
level in the different groups showed that induced diabetes 
by STZ cause damage to pancreatic beta cells and reduce 
blood insulin levels (21,27). In a study, Ravi et al showed 
that STZ can cause damage to the beta cells of the pancreas 
and decreased serum levels of insulin (28). This entry also 
w s confirmed by other studies (21,27). Treatment with 
Galega extr ct can be incr ased insulin levels that m y 
be due to the presence of compounds such as flavon ids, 
tannins, saponins, glycosides, resin, and steroids in this 
plant. Therefore, it has high antioxidant property and is 
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caused protection of beta cells against oxidative stress (24). 
Coskun et al showed that flavonoids can lower blood sugar, 
protect the beta cell against oxidative stress and maintain 
pancreatic beta cell integrity (29). Moreover, other studies 
have suggested that antioxidants can protect the beta cells 
against oxidative stress and prevent beta cell destruction 
(30,31). As results showed, antioxidant property of Galega 
increases serum insulin levels relative to glibenclamide. 
DM is a disease associated with metabolism, can cause a 
disturbance in lipid metabolism (33). In the present study 
by comparing the lipid profiles in different groups, we 
found that diabetes leads to increase levels of cholesterol, 
LDL, and triglycerides and also decrease HDL levels. This 
results are in line with the study of Husain et al study 
(32). On the other hand, in our study, the level of LDL 
in the diabetic control group relative to the normal group 
insignificantly increased. Serum level of lipid profile 
could be controlled during treatment by Galega extract. 
The extract of this plant significantly reduced levels of 
TG, cholesterol, and LDL and also increased the level of 
HDL. One of the reasons that why this plant can control 
lipid profile may be due to have abundant antioxidant 
compounds such as flavonoids (24). A study has shown 
that flavonoids can control blood lipid levels (34). The 
kidney is an organ that diabetes impairs their function 
so that increased blood levels of urea and creatinine 
are indicative of impaired in glomerular filtration (35), 
which is due to oxidative stress. Also, Ravi et al showed 
that the oxidative stress in diabetic rats can damage the 
liver and kidney tissues and also disrupt their functions. 
In the present study in diabetic rats, kidneys weight, the 
diameter of glomeruli, and the thickness of the basement 
membrane increased, and also the number of glomeruli, 
and diameter of the urinary spaces decreased which 
indicate damage to the kidney tissue and reduction in 
glomerular filtration (28). In agreement with our results, 
Sharma et al demonstrated that serum level of urea and 
creatinine increased in diabetes (36). Results of this study 
showed that treatment with G. officinalis extract can 
protect the kidney tissue against tissue damage which 
induced by oxidative stress related to diabetes. Decreasing 
the kidneys weight, reducing the diameter of glomeruli, 
increasing the number of glomeruli, increasing the 
diameter of the urinary spaces, decreasing the thickness 
of the basement membrane, and also decreasing the level 
of urea and creatinine in diabetic rats may be due to the 
presence of abundant antioxidant compounds of the 
plant (24). In agreement with our results, Sharma et al 
showed that antioxidants can reduce the level of urea and 
creatinine (36).
The liver is one of the other organs that diabetes has side 
effects on it in which the levels of GPT and ALP increase. 
Marzouk et al showed that diabetes leads to impair the 
metabolism of liver and increase levels of its enzymes 
(37). Moreover, Maritim et al found same results (38). 
According to the results of the present study, we observed 
that Galega extract reduced the level of GPT and also by its 
antioxidant property prevent the liver damage in diabetic 
rats. Marzouk et al showed that herbal antioxidants inhibit 
the increasing levels of liver enzymes (37).
Conclusion
The results of the present study indicated that G. officinalis 
could be beneficial for the treatment of diabetes and 
reducing the FBS through improving the serum level 
of insulin and preventing kidney tissue damages by 
antioxidant feature.
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